コンテンツへスキップ
Merck

A8800

Sigma-Aldrich

アルプラゾラム

別名:

8-クロロ-1-メチル-6-フェニル-4H-[1,2,4]トリアゾロ[4,3-a][1,4]ベンゾジアゼピン

ログイン組織・契約価格を表示する


About This Item

実験式(ヒル表記法):
C17H13ClN4
CAS番号:
分子量:
308.76
EC Number:
MDL番号:
UNSPSCコード:
12352200
PubChem Substance ID:
NACRES:
NA.77

形状

powder

品質水準

薬剤管理

USDEA Schedule IV; Home Office Schedule 4.1; psychotrope (France); kontrollierte Droge in Deutschland; regulated under CDSA - not available from Sigma-Aldrich Canada; psicótropo (Spain); Decreto Lei 15/93: Tabela IV (Portugal)

テクニック

HPLC: suitable
gas chromatography (GC): suitable

溶解性

H2O: insoluble
methanol: soluble

アプリケーション

forensics and toxicology
pharmaceutical (small molecule)
veterinary

オーガナイザー

Johnson & Johnson

SMILES記法

Cc1nnc2CN=C(c3ccccc3)c4cc(Cl)ccc4-n12

InChI

1S/C17H13ClN4/c1-11-20-21-16-10-19-17(12-5-3-2-4-6-12)14-9-13(18)7-8-15(14)22(11)16/h2-9H,10H2,1H3

InChI Key

VREFGVBLTWBCJP-UHFFFAOYSA-N

類似した製品をお探しですか? 訪問 製品比較ガイド

関連するカテゴリー

詳細

Alprazolam is a triazole-containing benzodiazepine that is related to diazepam and other 1,4-benxodiazepines. Like other benzodiazepines, Alprazolam is a GABAergic agonist that modulates GABAA receptors. GABAA receptors in the central nervous system are ligand-gated ion channels that are bound by the stimulatory neurotransmitter GABA; binding of this ligand allows ion movement through the channel and results in neurotransmission inhibition.

生物化学的/生理学的作用

Alprazolam binds the GABAA receptor at the benzodiazepine site, which is different than the ligand-binding site at which GABA binds. Alprazolam has been shown to be an anxiolytic (anti-anxiety agent) as well as having anticonvulsant, muscle relaxant and antidepressant activity.

特徴および利点

This compound is a featured product for Neuroscience research. Click here to discover more featured Neuroscience products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
This compound is featured on the GABAA Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Johnson & Johnson. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

ピクトグラム

Exclamation mark

シグナルワード

Warning

危険有害性情報

危険有害性の分類

Acute Tox. 4 Oral

保管分類コード

11 - Combustible Solids

WGK

WGK 3

引火点(°F)

Not applicable

引火点(℃)

Not applicable

個人用保護具 (PPE)

dust mask type N95 (US), Eyeshields, Gloves


適用法令

試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。

Jan Code

A8800-10MG-PW:
A8800-50MG-PW:
A8800-BULK:
A8800-50MG:4548173187716
A8800-10MG:4548173187709
A8800-VAR:


試験成績書(COA)

製品のロット番号・バッチ番号を入力して、試験成績書(COA) を検索できます。ロット番号・バッチ番号は、製品ラベルに「Lot」または「Batch」に続いて記載されています。

以前この製品を購入いただいたことがある場合

文書ライブラリで、最近購入した製品の文書を検索できます。

文書ライブラリにアクセスする

この製品を見ている人はこちらもチェック

An Overview of the CNS-Pharmacodynamic Profiles of Nonselective and Selective GABA Agonists
Chen, X., et al.
Advances in Pharmacological Sciences, 2012, 1-10 (2012)
G W Dawson et al.
Drugs, 27(2), 132-147 (1984-02-01)
Alprazolam is a triazolobenzodiazepine which is related to diazepam and other 1,4-benzodiazepines, and has a similar pharmacological profile. Relative to the newer benzodiazepines, alprazolam has an intermediate half-life of 10 to 12 hours in healthy young subjects. In placebo-controlled and
J M Jonas et al.
The Journal of clinical psychiatry, 54 Suppl, 25-45 (1993-10-01)
A review of the worldwide published literature was conducted to assess the efficacy and safety of alprazolam for the treatment of anxiety disorders, panic disorder, and depression in comparison with those of other active drugs (including other benzodiazepines and antidepressant
E M Sellers et al.
The Journal of clinical psychiatry, 54 Suppl, 64-75 (1993-10-01)
The incidence of nonmedical use of alprazolam is very low relative to its widespread legitimate medical use; in fact, given the millions of patients who have received this medication, the incidence is remarkably small. In particular, among patients with anxiety
J O Cole et al.
The Journal of clinical psychiatry, 54 Suppl, 49-61 (1993-10-01)
A review of the published case reports of adverse behavioral episodes or unexpected psychopathology in patients taking benzodiazepines was undertaken in an attempt to determine if these adverse or unexpected events are more likely to occur with alprazolam when compared

ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.

製品に関するお問い合わせはこちら(テクニカルサービス)